Hydroxychloroquine

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.

DESTIN, Fla. — Low disease activity and remission are achievable for patients with lupus if clinicians “minimize the prednisone” and administer adequate hydroxychloroquine, noted a speaker at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The overall risk for incident retinopathy in patients who received hydroxychloroquine for 5 or more years was low but progressively increased with higher doses, according to researchers.

KOLOA, Hawaii — Sequential macular thickness mapping can be used to detect retinal toxicity from hydroxychloroquine early and with specificity, according to a speaker here.

PHILADELPHIA — In patients with systemic lupus erythematosus, lower doses of hydroxychloroquine increase the risk for hospitalization due to flare, according to data presented at ACR Convergence 2022.

Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.

Prenatal exposure to hydroxychloroquine in birthing parents with systemic lupus erythematosus results in no significant adverse outcomes in children from breast feeding through 17 years, according to data published in Rheumatology.

DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.

Current hydroxychloroquine use in patients with rheumatoid arthritis or systemic lupus erythematosus is associated with a reduced risk for cardiovascular events, including ischemic stroke and myocardial infarction, according to data.